Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toho to Seek New Business Challenges Under Next 3-Year Plan
February 13, 2006
- Wako Pure Chemical: New Fecal Occult Blood Analyzer FOBITWAKO
February 13, 2006
- Sucampo Obtains FDA Approval for AMITIZA
February 13, 2006
- DPC Management Study Group Inaugurated
February 13, 2006
- BUSINESS NEWS IN BRIEF
February 13, 2006
- Korosho Announces Nutrition and Weight Gain GL for Pregnant, Nursing Mothers
February 13, 2006
- Focus on Pollinosis (2)
February 13, 2006
- JGPMA to Talk with JPMA About Job Sharing
February 13, 2006
- Focus on Pollinosis (1)
February 6, 2006
- NEW PRODUCTS
February 6, 2006
- New JP-listed Drugs to Receive Same Exceptional Price Cut as Non-listed Drugs
February 6, 2006
- OPINION
February 6, 2006
- Foreign Price Adjustment Rule to Be Toughened
February 6, 2006
- JPMA Announces GL on Licensing of Patents on Research Tools
February 6, 2006
- 21 New Drugs Approved
February 6, 2006
- R&D NEWS IN BRIEF
February 6, 2006
- Atypical Antipsychotic Abilify: Otsuka
February 6, 2006
- Proposed Revision of Medical Materials System Approved by Chuikyo
February 6, 2006
- Silodosin to Improve Dysuria: Kissei
February 6, 2006
- MEDICAL DEVICE NEWS IN BRIEF
February 6, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…